rheumatoid arthritis
Conditions
Interventions
Treatment group:CLA supplements are taken in addition to csDMARDs therapy
Control group:Treatment with csDMARDs
Sponsors
Dazhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.All met the 2010 American College of Rheumatology revised diagnostic criteria for RA; 2. RA patients aged =18 and =75 years with DAS28 =3.0; 3.Those who had received at least one csDMARDS (including methotrexate, hydroxychloroquine sulfate, leflunomide, and elamectin) with poor efficacy prior to enrollment; 4.Patients who were compliant, signed an informed consent form, and were able to complete the trial according to the protocol.
Exclusion criteria
Exclusion criteria: 1. Patients treated with biological agents; 2.Patients with malignant diseases such as peptic ulcer, hematologic diseases, mental disorders and tumors; 3. Patients with previous or current medical history of inflammatory joint diseases other than rheumatoid arthritis, or patients with other systemic autoimmune diseases in combination; 4.Persons with a recent history of major surgery or trauma; 5.The presence of concomitant poorly controlled disease that is considered by the investigator to be clinically significant and serious; 6.Poor compliance and inability to cooperate in completing the trial; 7.Those with a history of depressive illness and taking related medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease activity (DAS28 score);Swelling number;Tenderness number;Duration of joint morning stiffness;Joint dysfunction;Erythrocyte sedimentation rate (ESR);C-reactive protein;immune globulin (Ig);RF;CCP;IL-1ß;IL-6;TNF-a; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine index;TC;TG;HDL;LDL;UR;ALT;AST;CR;GFR;BMI; | — |
Countries
China
Contacts
Public ContactFanxing Zeng
Dazhou Central Hospital
Outcome results
None listed